Business Wire

Achiko Ltd.: Achiko and Hypothekarbank Lenzburg sign a Memorandum of Understanding to progress delivery of Achiko's digital wallet and financial services App in Switzerland

Share

Newly listed FinTech company Achiko Ltd. (ACHI:SWX) and Swiss bank Hypothekarbank Lenzburg AG (HBLN:SWX) announce their intention to enter into a partnership to deliver Achiko's digital financial platform offering in Switzerland.

Hypothekarbank Lenzburg (HBL), one of Switzerland's leading financial institutions in the ongoing digitalization of financial services, and Achiko, one of Asia's leading FinTech companies operating as a payment services platform and listed at the SIX Swiss Exchange, will deliver the platform by leveraging Achiko's digital infrastructure and HBL's Finstar(R) banking solution. The new platform will provide financial services including a digital wallet, which will set a new benchmark in terms of functionality and consumer engagement.

Marianne Wildi, CEO of Hypothekarbank Lenzburg Ltd: "With this cooperation we once more prove our leadership when it comes to Open Banking in Switzerland. The cooperation with Achiko is a milestone in the opening process of Swiss Banking for innovative Fintech solutions. We are happy that our bank and its core banking system Finstar is part of this dynamic."

Users who register for the Swiss offering of Achiko will automatically become a customer of HBL with a special account designed for the usage of the Achiko digital wallet. The user-friendly digital wallet will provide access to a range of products and services such as currency held in a bank account, digital commodities, enabling funds to be "topped up" from an account with HBL, issuance of "Achiko" co-branded debit or prepaid cards offered by HBL and a variety of payment mechanisms. In addition, Achiko's payroll advance system, called EarlyPay, will be rolled out during the course of 2020, enabling registered employees of companies who have enabled 'AchikoPay' to draw down an advance payment against their salary. The service will be free of charge to the employer while employees are charged a small administration fee.

The partnership with HBL and Achiko's new e-wallet is limited to the Swiss market. Nonetheless it is a sign of Achiko's ambition to expand its footprint both in terms of range of services, as well as geographically. To this end, Achiko continues to focus on the expansion of its core customer base in Asia, which will receive additional functionalities of the digital wallet within the next few months, while the company is also pro-actively exploring additional strategic partnerships, both in Europe as well as in Asia.

In order to promote and accelerate the implementation of its long-term expansion strategy, Achiko is also establishing a company in Switzerland.

Christopher Young, Chief Operations Officer of Achiko Ltd. and Director of the soon to be incorporated Achiko Switzerland AG, says: "Our recent decision to list Achiko on the SIX Swiss Exchange was a far-reaching strategic decision. Our aim is to enable people to connect through play and pay. We have a strong and rapidly growing business in Indonesia and Asia and in parallel we have strategic plans to increase our footprint in Switzerland and Europe. The partnership with leading institutions such as Hypothekarbank Lenzburg is an important steppingstone towards the implementation of this strategy. Further expansion of our services and additional partnerships are in the pipeline."

Going forward, the digital wallet will be a central part of Achiko's strategy. The company intends to bolt it into its payment services in Indonesia, use it as an anchor product in Europe, and believes that the suite of services (including 'buy now, pay later'-options, consumer credit, vouchers, offers, games services, etc.) may be relevant to broader Asia, Europe, and beyond.

About Achiko

Achiko is the holding company of the Mimopay and Kryptonite businesses. The group has branch offices in Indonesia, Hong Kong, Singapore and South Korea. Achiko has an experienced management team which has a track record building internationally recognised digital businesses and has also implemented them for companies like Disney, TimeWarner (now WarnerMedia), Samsung, Kakao, Leon Entertainment and many others.

Achiko has significant shareholders such as MNC Group, the largest media company in Southeast Asia. Its shareholder base also includes MOX, China's largest venture capital company focussing exclusively on the mobile sector and one of the three largest global VC companies in this field.

Further information can be found on www.achiko.co.

About Hypothekarbank Lenzburg and Finstar(R)

Hypothekarbank Lenzburg AG is a listed Swiss universal bank. Around 260 employees from 11 nations offer all banking services. The bank was founded in 1868 as Hypothekar- und Leihkasse Lenzburg. Today, the bank operates 13 branch offices and two consulting offices and is strongly anchored in the region. In addition to its traditional business, "Hypi" is also pushing ahead with the digitalization of the banking business. Finstar(R), the core banking system developed in-house, has open interfaces for Fintech companies and is also marketed as an open banking platform to third-party banks and other companies. In recent years, Hypothekarbank Lenzburg has received several awards for its innovative technological strength: "Finance IT Innovation Award" from Competence Center Ecosystem (2019), "Euro Finance Tech Award" from Euro Finance Tech (2017), "Most Digital Bank in Switzerland" from finews.ch (2016).

Further information can be found on www.hbl.ch

Disclaimer

This publication constitutes neither an offer to sell nor a solicitation to buy securities of the Company and it does not constitute a prospectus or a similar communication within the meaning of article 652a, 752 and/or 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange.

This communication is being distributed only to, and is directed only at (i) persons outside the United Kingdom, (ii) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth entities, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "Relevant Persons"). Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person must not act or rely on this communication or any of its contents.

This communication does not constitute an "offer of securities to the public" within the meaning of Regulation 2017/1129 of the European Union (the "Prospectus Regulation") of the securities referred to in it (the "Securities") in any member state of the European Economic Area (the "EEA"). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Regulation from the requirement to produce a prospectus for offers of the Securities.

The securities referred to herein have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States or to US persons (as such term is defined in Regulation S under the Securities Act) unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. The issuer of the securities has not registered, and does not intend to register, any portion of the securities in the United States, and does not intend to conduct a public offering of securities in the United States.

Contact information

Germany and Austria
Axel Mühlhaus / Dr. Sönke Knop
edicto GmbH E: achiko@edicto.de
T: +49 69 90 55 05-51

Switzerland
Marcus Balogh
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment7.12.2019 22:00:00 EETPress release

Kite, a Gilead Company (Nasdaq: GILD), today announced new data from the ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma. These results included updated overall survival data from the pivotal phase 2 study after three years following a single infusion of Yescarta, as well as an analysis from a separate safety management cohort of patients receiving early steroid intervention for cytokine release syndrome (CRS) and neurologic events. The data were presented today at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, in Orlando from December 7–10, 2019. With a minimum follow-up of three years after a single infusion of Yescarta (median follow-up of 39.1 months), approximately half (n=47/101; 47 percent) of patients with refractory large B-cell lymphoma in ZUMA-1 pivotal phase 2 cohorts were alive, and the median overall survival (OS) was 25.8 months. These updated three-year survival data were presented a

Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma7.12.2019 18:20:00 EETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being evaluated in the treatment of patients with relapsed or refractory multiple myeloma. The study enrolled patients who had received at least three prior lines of therapy or were double refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD); had received a PI, IMiD and an anti-CD38 antibody. The CARTITUDE-1 study results, premiered at the American Society of Hematology (ASH) Annual Meeting, were featured as an oral presentation and highlighted in the official ASH press programme (Abstract #577).1 Results from the Phase 1b portion of the CARTITUDE-1 study showed early and deep responses among patients (n=29) with a median of five prior multiple myeloma

Imbruvica®▼(ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukaemia7.12.2019 18:18:00 EETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced combination data from two studies and a long-term integrated analysis evaluating the use of Imbruvica® (ibrutinib) for the treatment of previously untreated patients with CLL. Results from a 48-month follow-up analysis of the Phase 3 E1912 clinical study reported a statistically significant difference in PFS and OS for ibrutinib plus rituximab compared to a standard chemoimmunotherapy regimen of FCR.1 Further, the latest integrated analysis from the Phase 3 RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115/1116) studies investigating the use of single-agent ibrutinib in CLL, reported at up to six years of follow-up, PFS, OS and response rates improved when ibrutinib was used in earlier lines of therapy.2 During this extended follow-up, ibrutinib was tolerated across all lines of therapy with 19 percent of patients discontinuing due to adverse events.2 In addition, results presented from the Phase 2 CAPTIVATE stu

Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis7.12.2019 17:30:00 EETPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019 in Orlando, Florida. TOURMALINE-AL1 is a Phase 3, randomized clinical trial evaluating the effect of NINLAROTM (ixazomib) in combination with dexamethasone in patients with relapsed or refractory systemic light-chain (AL) amyloidosis. The TOURMALINE-AL1 trial did not meet the first of the two primary endpoints of significant improvement in overall hematologic response, as reported in June 2019. Hematologic responses were seen in 53% versus 51% of patients receiving NINLARO plus dexamethasone versus physician’s choice (odds ratio 1.10 [95% CI 0.60-2.01], p=0.762) as assessed by an Adjudication Committee (AC). The second primary endpoint of two-year vital organ deterioration or death was not mature at the time of analysis. Other endpoints stu

Schlumberger Announces Fourth-Quarter and Full-Year 2019 Results Conference Call6.12.2019 21:07:00 EETPress release

Schlumberger Limited (NYSE:SLB) will hold a conference call on January 17, 2020 to discuss the results for the fourth quarter and full year ending December 31, 2019. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 4013483. A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 17, 2020, and can be accessed by dialing +1 (866) 207-1041 within North Amer

BUFF STUDIO Globally Launches My Coloring, a Mobile 3D Pixel Art Coloring Book Game6.12.2019 16:00:00 EETPress release

BUFF STUDIO announced on December 5 that it launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191206005162/en/ BUFF STUDIO launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. My Coloring is a game that materializes a 3D pixel art coloring book on mobile devices. You can blow your stress away as you paint spaces in the order of numbers on the screen while reading calming messages. Relaxing background music you will listen during gameplay and its fairytale-like design will give you pleasure and happiness. You can download it for free on Google Play and the Apple App Store. (Graphic: Business Wire) Its Android and iOS versions were released at the same time so the users can download it for free on Google Play and the Apple App Store. My Coloring is a game that materializes a 3D pixel art col

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom